February 2, 2018 (Hackensack, N.J.) -- Andrew L. Pecora, M.D., FACP, CPE, president, Physician Enterprise and chief innovations officer at Hackensack Meridian Health, was honored with the 2018 Dr. Sol J. Barer Award for Vision, Innovation and Leadership at the Gateway Gala, BioNJ’s 25th Annual dinner meeting, networking event and innovation celebration on Feb. 1 at the Hilton, East Brunswick, NJ.
“Andrew Pecora is a remarkable physician, researcher and innovator,” said Robert C. Garrett, co-CEO of Hackensack Meridian Health
. “This recognition is so well deserved because of Dr. Pecora’s outstanding leadership which has resulted in tangible improvements in patient outcomes and health care delivery. I am honored to call him a colleague and friend."
A certified hematologist and oncologist, Dr. Pecora is recognized internationally as one of the world’s foremost experts in blood and marrow stem cell transplantation, cellular medicine and immunology research. In 1989, he spearheaded the development of the John Theurer Cancer Center’s Adult Blood and Marrow Stem Cell Transplantation Program and is responsible for many advancements used in stem cell transplantation today.
Dr. Pecora’s current research involves developing vaccines and other cellular medicine techniques that boost the capabilities of a patient’s own immune system to fight cancer and targeted therapies that destroy cancer cells. His research has been published extensively in prestigious medical journals and he is a frequently requested lecturer at conferences all over the world.
A serial entrepreneur, Dr. Pecora has created multiple companies in biotechnology healthcare and information technology, and holds over 50 national and international patents covering the composition and use of bone marrow derived cells for treating cardiovascular disease and for applications in precision analytics. He is the founder and first president of Regional Cancer Care Associates and professor of oncology and medicine, Georgetown University.
In 2017, the Hackensack Meridian Health
Board of Trustees approved a $25 million capital fund to create incubator space, among other initiatives, to promote innovation, which has drawn interests from venture capitalists and life science companies.
“The work that Dr. Pecora is doing - for patients, for medicine, for science, for New Jersey - defines vision, innovation and leadership,” says BioNJ President and CEO Debbie Hart. “He is deserving of this award for what he has done and what he is sure to do in the future. Through his work, Dr. Pecora is disrupting the practice of medicine, disrupting innovation, disrupting our ecosystem and disrupting the future of health care. BioNJ is thrilled to honor this amazing man in this way and anxious to see his future unfold.”